검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Bispecific antibodies (bsAB) |
Overview Company | Akeso |
Overview Modality | ANTIBODY |
Overview Target | Cancer |
Overview Indication | Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | targets, such as CD98hc or transferrin receptor |
MoA Biomarker | PD-L1 (programmed death-ligand 1)-positive |
PK/PD Half-life | 51.9 h |
PK/PD Species | Cynomolgus monkey, Mouse |
PK/PD Animal (cat.) | Human, Mouse, NHP, Monkey, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse |
Toxicology Animal (cat.) | Human, Mouse, NHP, Monkey, In vitro |
Toxicology Major finding | EGFRxCD16 bispecific antibodies orchestrate superior NK cell-mediated lysis of ovarian cancer and NSCLC cell lines in combination with oncolytic viruses.. Combination therapy integrating bispecific antibody (BsAb) and oncolytic viruses (OVs) to enhance antitumor immune response offers a promising therapeutic approach in comparison with OV treatment alone. This study aims to strengthen and characte… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 11.1% |
Clinical ORR | 11.1% |
Clinical Result source | ClinicalTrials.gov NCT03340766 |
Clinical Data Tier / Score | A · 25 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Bispecific antibodies (bsAB) |
Overview Company | Akeso |
Overview Modality | ANTIBODY |
Overview Target | Cancer |
Overview Indication | Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | targets, such as CD98hc or transferrin receptor |
MoA Biomarker | PD-L1 (programmed death-ligand 1)-positive |
PK/PD Half-life | 51.9 h |
PK/PD Species | Cynomolgus monkey, Mouse |
PK/PD Animal (cat.) | Human, Mouse, NHP, Monkey, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse |
Toxicology Animal (cat.) | Human, Mouse, NHP, Monkey, In vitro |
Toxicology Major finding | EGFRxCD16 bispecific antibodies orchestrate superior NK cell-mediated lysis of ovarian cancer and NSCLC cell lines in combination with oncolytic viruses.. Combination therapy integrating bispecific antibody (BsAb) and oncolytic viruses (OVs) to enhance antitumor immune response offers a promising therapeutic approach in comparison with OV treatment alone. This study aims to strengthen and characte… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 11.1% |
Clinical ORR | 11.1% |
Clinical Result source | ClinicalTrials.gov NCT03340766 |
Clinical Data Tier / Score | A · 25 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교